In vivo CAR-T therapies could make one of medicine’s most sophisticated treatments far easier to deploy.
Source
- DCVC, Deep Tech Opportunities Report 2026 (opens in a new tab)6.3Published: 1 Jul 2026
Source thesis
DCVC discusses in-vivo CAR-T approaches intended to reduce the cost, waiting and specialised manufacturing associated with individually prepared cell therapies. The report includes Umoja as an example and describes investigational programmes; this is not evidence of general clinical availability or efficacy.